Long-term follow-up of axillary node-positive breast cancer patients receiving adjuvant systemic therapy alone: patterns of recurrence, Int.J.Radiat.Oncol.Biol.Phys., 38: 541-550, 1997.Fisher BJ, Perera FE, et al. (1998) Long-term follow-up of axillary node-positive breast cancer patients ...
Locally advanced rectal cancer (LARC) poses a significantly challenge in clinical management, requiring a multimodal treatment approach. Among innovative strategies, Total Neoadjuvant Therapy (TNT) has emerged, delivering all planned chemotherapy before
Scrambler therapy involves the use of a device to treat pain via noninvasive cutaneous electrostimulation. This strategy was reported to be beneficial as a noninvasive method for some cancer patients in earlier pilot trials. However, the latest pilot randomised trial showed no beneficial effect of ...
Executive function symptom levels (b: 4.1; 95% CI =7.8, 0.4) were significantly lower for cancer survivors who received chemotherapy, compared with those receiving locoregional treatment. In cancer survivors who received other systemic therapy, memory (b: 0.4; 95% CI =0.1, 0.7) and executive ...
presuming it to be a reasonable time interval. Hie decision to discharge patients from a follow-up clinic is also difficult and may be left to a junior colleague. Decisions about follow-up are made all the more difficult in cancer patients, because of the stigma attached to the disease and...
This 70-year-old man with stage IV non-small-cell lung cancer (NSCLC) with multiple brain metastases and a large primary tumor in his right lung underwent standard initial therapy with whole brain radiation and combination chemotherapy. The chemotherapy regimen containing gemcitabine and carboplatin ...
Citation11 However, the effectiveness of surgery and systemic therapy following detection of recurrence is not well explored. While those receiving surgery for recurrent colon cancer have been reported to have a 5-year survival of up to 30%,Citation12 the prognosis for pelvic recurrent rectal ...
Cancer Res. 2016;76(4):S1-S3.Google Scholar 10. Emens LA, Cruz C, Eder JP, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study [published online September 13, 2018]. JAMA Oncol. do...
with the primary aim of observing high-frequency SD-OCT changes our study was not powered for a statistical safety analysis. At least for systemic adverse events we know that for cancer treatment systemic anti-VEGF therapy (like bevacizumab) is applied on a biweekly basis with an acceptable ...
A careful assessment and management of early and late side-effects of different BC treatments (including surgery, radiotherapy and systemic therapy) should represent one of the main aims of the surveillance program [6], [7], [8]. Thus, the clinicians should provide the patient with a cancer ...